alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

31,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26–50 of 58 studies with an author at Universidade de São Paulo (BR) · free to read (page 2 of 3) · 31,780 in the whole library · How the 0–100 score works

Download bibliography of these 58 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 17,251 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The 2022 symposium on dementia and brain aging in low- and middle-income countries: Highlights on research, diagnosis, care, and impact

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2024-05-02

Two of every three persons living with dementia reside in low- and middle-income countries (LMICs). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study)

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Arquivos de neuro-psiquiatria 2014-06-01

Twenty-one patients received at least one drug dose (9 GAL/NIM and 12 GAL/PLA). 3 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Dementia in Latin America: Paving the way toward a regional action plan

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2020-11-20

Across Latin American and Caribbean countries (LACs), the fight against dementia faces pressing challenges, such as heterogeneity, diversity, political instability, and socioeconomic disparities. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Undiagnosed dementia and mortality among older adults in the United States and Brazil: A cross-national cohort study

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Alzheimer's & Dementia 2026-04-29

Undiagnosed dementia is common and associated with increased mortality, identifying a vulnerable population missed by current diagnostic pathways. 3 key findings →

Design: cohort Participants: 13,142 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Pulling Back the Curtain on Hospital Dementia Detection: Validation of the Informant‐Based Clinical Dementia Rating

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Journal of the American Geriatrics Society 2025-05-02

Of 65 participants (mean age = 79.4 years; women = 54%), 34% had dementia and 32% had CIND. 5 key findings →

Design: cross-sectional Participants: 65 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Ultraprocessed Foods and the Risk of Cognitive Impairment and Dementia in Older US Adults: 2013-2020 Health and Retirement Study

✓ Peer-reviewed alzhub usefulness score 53 out of 100. American Journal of Public Health 2026-06-03

Increased UPF consumption is associated with higher risks of dementia, CIND, and CIND or dementia among US older adults. 4 key findings →

Design: cohort Participants: 5,370 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cholesterol metabolism in aging simultaneously altered in liver and nervous system

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Aging 2022-02-07

In humans, aging, triggers increased plasma concentrations of triglycerides, cholesterol, low-density lipoproteins and lower capacity of high-density lipoproteins to remove cellular cholesterol. 4 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Inflammation and Oxidative Stress: The Molecular Connectivity between Insulin Resistance, Obesity, and Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Mediators of inflammation 2015-11-26

Type 2 diabetes (T2DM), Alzheimer's disease (AD), and insulin resistance are age-related conditions and increased prevalence is of public concern. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Single-cell resolution characterization of myeloid-derived cell states with implication in cancer outcome

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Nature communications 2024-07-07

Tumor-associated myeloid-derived cells (MDCs) significantly impact cancer prognosis and treatment responses due to their remarkable plasticity and tumorigenic behaviors. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cardiovascular risk factors and the allostatic interoceptive network in dementia

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Cardiovascular Research 2025-10-01

We recruited 1501 participants (304 with FTLD, 512 with AD, and 685 healthy controls) from the Multi-Partner Consortium to Expand Dementia Research in Latin America (ReDLat). 5 key findings →

Participants: 1,501 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Polyphenols, Alkaloids, and Terpenoids Against Neurodegeneration: Evaluating the Neuroprotective Effects of Phytocompounds Through a Comprehensive Review of the Current Evidence

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Metabolites 2025-02-13

They remain a significant focus of scientific and clinical interest due to their increasing medical and social importance. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Genetic contributions to Alzheimer’s disease and frontotemporal dementia in admixed Latin American populations

✓ Peer-reviewed alzhub usefulness score 48 out of 100. npj Dementia 2026-01-21

Latin America’s diverse genetic landscape provides a unique opportunity to study Alzheimer’s disease (AD) and frontotemporal dementia (FTD). 1 key finding →

Participants: 2,162 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

White matter hyperintensities and their impact in brain structure and function in alzheimer’s disease and behavioral variant frontotemporal dementia across Latin America and the United States: a cross-sectional study

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Alzheimer s Research & Therapy 2025-08-12

In the LA cohort only, higher WMHs load was associated with greater GM atrophy across all groups (HCs, AD, bvFTD), with a specific neurodegenerative pattern involving orbitofrontal, cingulate, and temporal areas. 5 key findings →

Participants: 402 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Intermittent fasting attenuates lipopolysaccharide-induced neuroinflammation and memory impairment

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of neuroinflammation 2014-05-06

Our results suggest that IF induces adaptive responses in the brain and periphery that can suppress inflammation and preserve cognitive function in an animal model of systemic bacterial infection. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomized / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multicenter collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 31,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,780 records, built mostly from automated pulls of Europe PMC (66% of the library) and OpenAlex (16%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,052 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events